Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 367 Ovarian Neoplasms 99 Lung Neoplasms 98 Neoplasms 84 Small Cell Lung Carcinoma 71 Breast Neoplasms 59 Neoplasm Metastasis 49 Triple Negative Breast Neoplasms 46 Parkinson Disease 4, Autosomal Dominant Lewy Body 41 Fallopian Tube Neoplasms 38 Squamous Cell Carcinoma of Head and Neck 33 Endometrial Neoplasms 30 Carcinoma 30 Uterine Cervical Neoplasms 28 Colorectal Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Head and Neck Neoplasms 19 Carcinoma, Transitional Cell 18 Urinary Bladder Neoplasms 17 Advanced Solid Tumors 17 Recurrence 15 Melanoma 14 Stomach Neoplasms 13 Peritoneal Neoplasms 13 Pancreatic Neoplasms 12 Adenocarcinoma 11 Lung Diseases 9 Glioblastoma 9 Carcinoma, Squamous Cell 9 Thoracic Neoplasms 8

Interventions

pembrolizumab 3 relatlimab 1 lifileucel 1 dabrafenib 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma, Cutaneous Malignant × Carboplatin × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡